Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598209 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30802551 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29367497 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29355082 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL119575 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29624621 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| Fluoride SCHEMBL7155195 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30562127 | 0.96 | MDM4 (0.53) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29400671 | 0.92 | MDM4 (0.52) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL9072218 | 0.91 | MDM4 (0.50) | MDM4TP53CASP3MDM2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-114133428-B | Amphotericin B hydrophilic polypeptide derivative and application thereof | 华东理工大学 | 2023-10-27 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-1649625-A | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | UNIV TULANE (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050070470-A1 | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE | 2005-03-31 | — | — | US | disclosed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1487493-A2 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | The Administrators of The Tulane Educational Fund (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6787612-B1 | PRODUCING SUCH AS HYDRAZYL-CARBONYL-AMINO METHYLATED POLYSTYRENE; MINIMIZES SOLUTION-PHASE SYNTHETIC STEPS IN SOLID-PHASE PEPTIDE OR PEPTIDE ANALOG SYNTHESIS | DENDREON CORPORATION | 2004-09-07 | — | — | US | disclosed |
| EP-1435826-A2 | DIAGNOSTIC OR THERAPEUTIC SOMATOSTATIN OR BOMBESIN ANALOG CONJUGATES AND USES THEREOF | The Administrators of The Tulane Educational Fund (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003074551-A2 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003028527-A2 | DIAGNOSTIC OR THERAPEUTIC SOMATOSTATIN OR BOMBESIN ANALOG CONJUGATES AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2003-04-10 | — | — | WO | disclosed |
| EP-1100812-A2 | RESIN DERIVATIZATION METHOD AND USES THEREOF | CORVAS INTERNATIONAL, INC. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005243-A2 | RESIN DERIVATIZATION METHOD AND USES THEREOF | CORVAS INTERNATIONAL INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | MDM4 3785/4885TP53 383/4885CASP3 619/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.